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Background Trivalent, Ann Arbor strain, live attenuated inﬂuenza
vaccine (LAIV) is approved in several countries for use in eligible
children aged ‡2 years.
Objective To describe the safety of Ann Arbor strain LAIV in
children aged 2–17 years.
Methods An integrated analysis of randomized, controlled trials
of LAIV.
Results A total of 4245 and 10 693 children received ‡1 dose of
LAIV in year 1 of 6 trivalent inactivated inﬂuenza vaccine (TIV)-
controlled and 14 placebo-controlled studies, respectively; 3212
children were revaccinated in year 2 of 4 placebo-controlled
studies. Compared with placebo for days 0–10 post-vaccination,
LAIV recipients exhibited increased runny⁄stuffy nose (+7%),
headache (+7%), and tiredness⁄decreased activity (+2%) after
dose 1; and a higher rate of decreased appetite (+4%) after year 2
revaccination. Compared with TIV, only runny⁄stuffy nose was
increased (dose 1, +12%; dose 2, +4%). Compared with initial
vaccination, LAIV reactogenicity was lower after dose 2 in year 1
and revaccination in year 2. Unsolicited adverse events (AEs)
increased with LAIV in some comparisons were headache, nasal
congestion⁄rhinorrhea, rhinitis, and pyrexia; ear pain and lower
respiratory illness were decreased. There was no evidence of an
increase in any potential vaccine-related serious AE in LAIV
recipients. Among children aged 2–17 years and speciﬁcally aged
24–35 months, there was no evidence that lower respiratory illness
or wheezing illness occurred at a higher rate in LAIV recipients.
Conclusion This analysis supports the safety of Ann Arbor strain
LAIV in children aged 2–17 years and provides a consensus
assessment of events expected after vaccination.
Keywords Adverse events, Ann Arbor strain live attenuated
inﬂuenza vaccine, reactogenicity events, trivalent inactivated
inﬂuenza vaccine.
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Introduction
A trivalent, intranasal, live attenuated inﬂuenza vaccine
(LAIV) manufactured by MedImmune (Gaithersburg, MD,
USA) is currently approved for use in individuals aged 2–
49 years in the United States, South Korea, Israel, Hong
Kong, and Macau; in Canada in individuals 2–59 years of
age; and in the European Union in children 2–17 years of
age. The vaccine was originally derived at the University of
Michigan by cold adaptation of an inﬂuenza type A strain
(A⁄Ann Arbor⁄6⁄60 H2N2) and a type B strain (B⁄Ann
Arbor⁄1⁄66) through serial passage at sequentially lower
temperatures.
1 During this process, the Ann Arbor strains
acquired multiple mutations in genes encoding internal
non-glycosylated proteins, resulting in master donor viruses
with a cold-adapted, temperature-sensitive, and attenuated
phenotype. These vaccine strains are updated annually to
include A⁄H3N2, A⁄H1N1, and Type B inﬂuenza strains
with hemagglutinin (HA) and neuraminidase (NA) pro-
teins that match those of the strains selected for the speciﬁc
annual formulation. A frozen formulation of trivalent Ann
Arbor strain LAIV was ﬁrst licensed in 2003 in the United
States. A refrigerated formulation was licensed in 2007,
based on the demonstration of comparable immunogenicity
and safety.
2 Both formulations contain 10
6Æ5–10
7Æ5 ﬂuores-
cent focus units of each of the three virus strains per dose,
with no preservatives or adjuvants.
Ann Arbor strain LAIV has been used extensively in the
United States, with the majority of use occurring in chil-
dren, adult healthcare workers, and US military personnel.
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between licensure in 2003 and November 2010. In three
randomized studies comparing Ann Arbor strain LAIV and
trivalent inactivated inﬂuenza vaccine (TIV) in children
aged 6 months to 17 years, LAIV recipients had 35–53%
fewer cases of culture-conﬁrmed inﬂuenza.
3–5 Additionally,
LAIV has demonstrated effectiveness in children and adults
against inﬂuenza strains that were antigenically mismatched
to those contained in the vaccine.
6,7 Nasal administration
has facilitated use of the vaccine in mass vaccination and
alternative-site clinics such as school-based inﬂuenza vacci-
nation programs.
8–13
The safety of Ann Arbor strain LAIV has been studied in
more than 140 000 subjects in 73 completed or ongoing
studies in multiple regions of the world. The safety of LAIV
has been generally comparable with placebo and TIV in these
studies; however, one study demonstrated that, compared
with TIV, LAIV was associated with an increased rate of all-
cause hospitalization among children aged 6–11 months and
an increased rate of medically attended wheezing in children
aged 6–23 months. There was no increase in hospitalizations
in children aged ‡12 months and no increase in medically
attended wheezing in children aged ‡24 months.
3
Although the safety of Ann Arbor strain LAIV was ana-
lyzed for individual studies, an integrated analysis of safety
across these studies has not been conducted. To enhance
the understanding of the safety of LAIV in children for
whom it is approved, an integrated safety analysis was con-
ducted for subjects 2–17 years of age. The goals of this
analysis were to describe solicited reactogenicity events,
unsolicited adverse events (AEs), and serious AEs (SAEs)
associated with LAIV administration.
Methods
Study design
All clinical studies conducted with the Ann Arbor strain
LAIV were reviewed for inclusion, with a data cutoff date
of April 2008. Studies were included if any subjects were
2–17 years of age and if a randomized control group of
placebo or TIV recipients was included. Ongoing studies
and studies without individual subject data were excluded.
Overall, 20 studies contributed to the integrated analysis.
Subject demographics summarized included age, gender,
and region but not race or ethnicity, because these data
were not collected by common terms across the studies.
Reactogenicity events, AEs, and SAEs
For reactogenicity events and AEs, only data from subjects
who received the refrigerated formulation were analyzed to
optimize relevance. However, data from studies using fro-
zen and refrigerated LAIV were combined for SAE analyses
to maximize detection of a rare SAE. Classiﬁcation of AEs
and SAEs was consistent with the International Conference
on Harmonisation Guidelines for Good Clinical Practice.
Reactogenicity events were pre-deﬁned AEs that were
actively solicited after study product administration and
included runny⁄stuffy nose, sore throat, cough, vomiting,
headache, muscle ache, chills, decreased activity, irritability,
abdominal pain, decreased appetite, and fever. Reactogenic-
ity events may also have been collected as AEs (e.g. a reac-
togenicity event of runny⁄stuffy nose may have been
reported as a rhinitis⁄rhinorrhea AE) in accordance with
study design and investigator judgment.
Reactogenicity events and AEs were summarized
through 11 days (days 0–10 post-vaccination). Serious
adverse events were summarized from day of vaccination
through 42 days after the last dose, because this was the
data collection period in common across most studies,
and from day of vaccination to day 180 after the last dose
for those studies that collected safety information for this
period, which represents the longest duration of follow-up.
Adverse events and SAEs were summarized by system
organ class and preferred term using MedDRA version 8.0
(MedDRA MSSO, Chantilly, VA, USA) and by investiga-
tor-reported severity. To calculate incidence, each subject
contributed only once to a category. Adverse events and
SAEs because of lower respiratory illness and wheezing
were analyzed as events of special interest in the entire
population and speciﬁcally in children 24–35 months of
age. All reported AEs considered to be related to wheezing,
asthma, bronchial obstruction, or bronchospasm (includ-
ing bronchiolitis) were grouped into wheezing events of
special interest for analysis. A similar lower respiratory ill-
ness category included, in addition to all wheezing events
of special interest, any term that referred to disease of the
lower respiratory system or to respiratory difﬁculty.
Statistical analysis
Rate differences were calculated as the LAIV rate minus the
comparator (TIV or placebo) rate. Although all analyses
are descriptive in nature, Fisher’s exact P-values were calcu-
lated for rate differences between LAIV and comparator
groups for reactogenicity events, AEs, and SAEs for the
purpose of screening for differences of potential signiﬁ-
cance. No adjustment was made for multiplicity, and P-val-
ues presented should be interpreted in this context.
Results
Subject disposition and demographics
Data were available for 4245 and 10 693 subjects aged 2–
17 years who received at least one dose of LAIV in the ﬁrst
year of six TIV-controlled and 14 placebo-controlled stud-
ies, respectively (Tables 1 and 2). Data were available for
3212 subjects aged 2–7 years who were revaccinated with
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(Table 2); some subjects did not provide data for the year
1 analysis because they were aged <2 years in year 1. For
the analysis of a second dose in the ﬁrst year of dosing,
subjects aged <9 years who received the same study vaccine
at dose 1 and dose 2 were included. Because some studies
randomized children to a single dose in year 1, population
sizes for ﬁrst and second dose analyses differed; similarly,
populations for year 1 vaccination and year 2 revaccination
differed because there were a limited number of 2-year
studies. In placebo-controlled studies, more subjects
received LAIV than placebo as a result of randomization
ratios. In year 1, study follow-up was completed by 95Æ9%
of subjects, 2Æ0% were lost to follow-up, and 1Æ6% with-
drew consent; the remainder did not complete because of
protocol violations, investigator decisions, or other reasons.
Only ﬁve subjects (LAIV, n = 2; placebo, n = 2; TIV,
n = 1) withdrew because of an AE. Study completion and
discontinuation rates were similar for individuals who
received LAIV in year 2 and across treatment groups in
both years. Demographic data are shown in Table 2; results
were similar for LAIV, TIV, and placebo recipients for each
corresponding comparison group.
Solicited reactogenicity events days 0–10
post-vaccination
In all studies, reactogenicity events were common in all
study groups, including placebo, after the ﬁrst dose of vac-
cine. In TIV-controlled studies, the only reactogenicity
event that was statistically increased among LAIV recipients
was runny⁄stuffy nose (rate differences, 11Æ8% after dose 1
and 4Æ1% after dose 2; P <0 Æ01 for both); runny⁄stuffy
nose was also the most commonly reported reactogenicity
event (Figure 1). For all other reactogenicity events, the
rate difference was £1Æ5% points. After dose 1, the inci-
dence of muscle aches was lower in LAIV than in TIV
recipients (P =0 Æ04). Overall, the incidence of reactogenici-
ty events was lower among LAIV and TIV recipients after
the second dose of vaccine.
In placebo-controlled studies, the most common reactog-
enicity event was runny⁄stuffy nose, which was statistically
increased in LAIV recipients only after dose 1 (rate differ-
ence, 6Æ8%; P <0 Æ01) (Figure 2). Headache (rate difference,
6Æ9%; P =0 Æ02) and tiredness⁄decreased activity (rate dif-
ference, 2Æ1%; P =0 Æ03) were also signiﬁcantly increased
among LAIV recipients after dose 1. No other reactogenici-
ty events were signiﬁcantly increased, and all had rate
Table 1. Number of subjects in safety populations from TIV- and placebo-controlled clinical studies
AE and reactogenicity event populations
(refrigerated LAIV)
Year 1
Year 2 Dose 1 Dose 2
TIV-controlled studies
Reactogenicity event population: LAIV 4108 2187 NA
Reactogenicity event population: TIV 4118 2223 NA
AE population: LAIV 4147 2230 NA
AE population: TIV 4182 2270 NA
Placebo-controlled studies
Reactogenicity event population: LAIV 3245 2503 2287
Reactogenicity event population: Placebo 1994 1702 1248
AE population: LAIV 3278 2533 2295
AE population: Placebo 2026 1734 1256
SAE populations
(Frozen & Refrigerated LAIV)
Year 1 Year 2
Days 0–42 PLD Days 0–180 PLD Days 0–42 PLD Days 0–180 PLD
TIV-controlled studies
LAIV 4245 4130 NA NA
TIV 4278 4163 NA NA
Placebo-controlled studies
LAIV 10 693 2408 3212 2295
Placebo 5667 1546 1697 1256
AE, adverse event; LAIV, Ann Arbor live attenuated inﬂuenza vaccine; NA, data not available; PLD, post-last dose (dose 1 or, if administered, dose
2); SAE, serious AE; TIV, trivalent inactivated inﬂuenza vaccine.
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SAE population Reactogenicity event⁄AE population
TIV-controlled Placebo-controlled TIV-controlled Placebo-controlled
Year 1 Year 1 Year 2 Year 1 Year 1 Year 2
LAIV TIV LAIV Placebo LAIV Placebo LAIV TIV LAIV Placebo LAIV Placebo
Number of subjects 4245 4278 10 693 5677 3212 1697 4147 4182 3278 2026 2295 1256
Age, year Mean (SD) 4Æ9( 3 Æ9) 4Æ8( 3 Æ8) 5Æ8( 4 Æ3) 5Æ7( 4 Æ4) 3Æ0( 1 Æ1) 2Æ9( 1 Æ0) 4Æ9( 3 Æ9) 4Æ8( 3 Æ8) 2Æ4( 2 Æ0) 2Æ7( 2 Æ7) 2Æ6( 0 Æ6) 2Æ6( 0 Æ6)
Range 2–17 2–17 2–17 2–17 2–7 2–7 2–17 2–17 2–17 2–17 2–4 2–4
Age, 24–35 month, n 1650 1647 4117 2383 1223 660 1650 1647 3149 1900 1063 574
Age, 36–59 month, n 1219 1247 1636 790 1615 866 1219 1247 11 4 1232 682
Age, 5–17 year, n 1376 1384 4940 2504 374* 171* 1278 1288 118 122 0 0
Gender, % Male 53Æ85 5 Æ55 0 Æ05 0 Æ05 1 Æ14 9 Æ45 3 Æ95 5 Æ75 2 Æ35 1 Æ25 3 Æ04 9 Æ5
Region, %
USA 22Æ12 2 Æ46 8 Æ76 3 Æ42 8 Æ52 6 Æ02 0 Æ32 0 Æ60 Æ50 Æ80 Æ00 Æ0
Asia⁄Oceania
  3Æ13 Æ11 4 1 7 Æ52 5 Æ43 1 Æ23 Æ23 Æ24 5 Æ74 8 Æ93 5 Æ54 2 Æ1
Latin America 0Æ00 Æ07 Æ86 Æ51 5 Æ79 Æ80 Æ00 Æ02 5 Æ01 7 Æ82 2 Æ01 3 Æ2
Africa
  0Æ00 Æ02 Æ72 Æ71 1 Æ68 Æ00 Æ00 Æ08 Æ87 Æ71 6 Æ21 0 Æ8
Europe
§ 74Æ87 4 Æ56 Æ79 Æ91 8 Æ82 5 Æ07 6 Æ57 6 Æ21 9 Æ92 4 Æ82 6 Æ43 3 Æ8
AE, adverse event; LAIV, live attenuated inﬂuenza vaccine; SAE, serious AE; TIV, trivalent inactivated inﬂuenza vaccine; USA, United States of
America.
*Age 5–7 year.
 East Asia, Southeast Asia, South Asia, and Australia.
 South Africa only.
§Western Europe, Eastern Europe including Scandinavia, Lebanon, and Israel.
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Figure 1. Solicited reactogenicity events days
0–10 post-vaccination in TIV-controlled
studies. *P <0 Æ05, unadjusted for multiplicity.
LAIV, live attenuated inﬂuenza vaccine; TIV,
trivalent inactivated inﬂuenza vaccine.
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actogenicity events was lower for both treatment groups
compared with dose 1. The only statistically signiﬁcant dif-
ference between LAIV and placebo recipients after dose 2
was a lower rate of decreased appetite among LAIV recipi-
ents (rate difference, )2Æ9%; P =0 Æ04). Upon revaccination
in year 2 (Figure 3), the only statistically signiﬁcant differ-
ence was a higher rate of decreased appetite among LAIV
recipients (rate difference, 3Æ9%; P =0 Æ03). Data for head-
ache, muscle ache, and chills were not collected in year 2
of any studies.
When reactogenicity events were analyzed by number of
days reported, the median number of days for runny⁄stuffy
nose and cough for LAIV, placebo, and TIV recipients was
4–5 days. Median values were £3 days for decreased appe-
tite and sore throat, £2 days for irritability, abdominal
pain, tiredness⁄decreased activity, headache, muscle aches,
and chills, and 1 day for elevated temperatures and vomit-
ing. When LAIV recipients were compared with TIV or
placebo recipients, the difference in the median number of
days for each reactogenicity event was £1 day.
Unsolicited AEs days 0–10 post-vaccination
In TIV-controlled studies, during days 0–10 after dose 1,
more LAIV recipients reported ‡1 AE (rate difference,
2Æ7%; P <0 Æ01); rates were similar for both groups after
dose 2 (Table 3). Statistically signiﬁcant rate differences
were seen in infections (1Æ5%; P <0 Æ01), nervous system
disorders (0Æ6%; P =0 Æ04), and respiratory disorders
(1Æ5%; P <0 Æ01) after dose 1. The rate differences in ner-
vous system and respiratory disorders were primarily
attributable to headache (0Æ6%; P =0 Æ03) and nasal conges-
tion and rhinorrhea (0Æ3%; P =0 Æ01 and 1Æ2%; P <0 Æ01),
respectively. The infection increase could not be attributed
to a speciﬁc AE, but the largest rate difference (0Æ4%,
P =0 Æ10) was in rhinitis. Fewer surgical procedures were
reported in LAIV recipients after dose 2 (rate difference,
0Æ4%; P =0 Æ02), which was attributed to increased
reports of prophylaxis (i.e. preoperative administration of
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Figure 2. Solicited reactogenicity events days
0–10 post-vaccination in year 1 of placebo-
controlled studies. *P <0 Æ05, unadjusted for
multiplicity. LAIV, live attenuated inﬂuenza
vaccine.
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Figure 3. Solicited reactogenicity events days 0–10 post-vaccination in
year 2 of placebo-controlled studies. Data for headache, muscle ache,
and chills were not collected in year 2 of any studies. *P <0 Æ05,
unadjusted for multiplicity. LAIV, live attenuated inﬂuenza vaccine.
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P <0 Æ01). Rates of lower respiratory illness and wheezing
illness were similar among LAIV and TIV recipients after
dose 1 and dose 2.
In placebo-controlled studies, the percentage of subjects
reporting ‡1 AE was similar in the LAIV and placebo groups
in days 0–10 after dosing in years 1 and 2 (Table 4). A statis-
tically signiﬁcant rate difference for general disorders (2Æ2%;
P <0 Æ01) was observed after dose 1. This difference was
attributable to an increased rate of pyrexia among LAIV
recipients (rate difference, 2Æ1%; P <0 Æ01). After dose 2 in
year 1, fewer LAIV recipients reported ear disorders (rate
difference, )0Æ3%; P =0 Æ02), which was because of more
reports of ear pain among placebo recipients (rate differ-
ence, )0Æ2%; P =0 Æ04). Fewer lower respiratory illnesses
were reported among LAIV recipients (rate difference,
)1Æ0%; P =0 Æ03). In year 2, rates of reported AEs were simi-
lar between LAIV and placebo recipients.
When all AEs were analyzed by severity, the majority of
AEs reported in TIV- and placebo-controlled studies were
mild. Adverse event severity was similar between LAIV and
the corresponding TIV or placebo comparison groups.
SAEs days 0–42 and 0–180 post-vaccination
Rates of SAEs occurring through day 42 after the last dose
of vaccine were low and similar among LAIV, TIV, and
placebo recipients. In TIV-controlled studies, 0Æ75% of
LAIV recipients and 1Æ01% of TIV recipients reported any
SAE. Similarly, in placebo-controlled studies, 0Æ5% of LAIV
and 0Æ6% of placebo recipients reported any SAE in year 1
and 0Æ5% of LAIV and 0Æ6% of placebo recipients reported
any SAE in year 2. When SAEs were summarized by system
organ class, no statistically signiﬁcant differences were seen
between LAIV and TIV or placebo groups in year 1 or year
2; all rate differences were <0Æ025%. No signiﬁcant differ-
ences were seen for lower respiratory or wheezing illness;
rates were either similar or lower in LAIV recipients com-
pared with TIV or placebo recipients.
Similarly, when the available data were analyzed through
day 180 after the last dose, rates of any SAE were similar
among LAIV and TIV or placebo recipients. In TIV-con-
trolled studies, 2Æ3% of LAIV recipients and 2Æ5% of TIV
recipients reported any SAE. In placebo-controlled studies,
2Æ9% of LAIV and 2Æ7% of placebo recipients reported any
SAE in year 1, and 2Æ1% of LAIV and 1Æ7% of placebo
recipients reported any SAE in year 2. When analyzed by
system organ class, the only statistically signiﬁcant differ-
ence was an increase in the rate of injuries⁄poisonings
among LAIV versus placebo recipients in year 1 (LAIV,
0Æ3%; placebo, 0Æ0%; P =0 Æ05). No statistically signiﬁcant
differences were seen for lower respiratory or wheezing ill-
ness.
Table 3. Adverse events (AEs) during days 0–10 after LAIV and TIV administration in TIV-controlled studies
AEs
Year 1, dose 1 Year 1, dose 2
LAIV,
n (%)
TIV,
n (%)
Rate
difference*
LAIV,
n (%)
TIV,
n (%)
Rate
difference*
Total number of events, n 1292 1103 528 519
Subjects reporting ‡1 events 860 (20Æ7) 755 (18Æ1) 2Æ7 359 (16Æ1) 363 (16Æ0) 0Æ1
Events by organ class with absolute rate difference ‡0Æ10%
Infections and infestations 329 (7Æ9) 267 (6Æ4) 1Æ5
  192 (8Æ6) 175 (7Æ7) 0Æ9
Respiratory, thoracic and mediastinal disorders 270 (6Æ5) 209 (5Æ0) 1Æ5
  92 (4Æ1) 97 (4Æ3) )0Æ1
Nervous system disorders 79 (1Æ9) 55 (1Æ3) 0Æ6
  5( 0 Æ2) 7 (0Æ3) )0Æ1
Eye disorders 44 (1Æ1) 32 (0Æ8) 0Æ31 6 ( 0 Æ7) 12 (0Æ5) 0Æ2
Psychiatric disorders 27 (0Æ7) 16 (0Æ4) 0Æ34 ( 0 Æ2) 8 (0Æ4) )0Æ2
General disorders and administration site conditions 112 (2Æ7) 109 (2Æ6) 0Æ16 1 ( 2 Æ7) 67 (3Æ0) )0Æ2
Skin and subcutaneous tissue disorders 55 (1Æ3) 55 (1Æ3) 0Æ01 23 (1Æ0) 15 (0Æ7) 0Æ4
Surgical and medical procedures 5 (0Æ1) 7 (0Æ2) )0Æ05 1 (0Æ0) 9 (0Æ4) )0Æ4
 
Immune system disorders 1 (0Æ0) 5 (0Æ1) )0Æ11 ( 0 Æ0) 1 (0Æ0) 0Æ0
Ear and labyrinth disorders 10 (0Æ2) 16 (0Æ4) )0Æ19 ( 0 Æ4) 8 (0Æ4) 0Æ1
Events of interest
Lower respiratory illness 93 (2Æ2) 110 (2Æ6) )0Æ45 1 ( 2 Æ3) 60 (2Æ6) )0Æ4
Wheezing illness 59 (1Æ4) 68 (1Æ6) )0Æ21 9 ( 0 Æ9) 30 (1Æ3) )0Æ5
LAIV, Ann Arbor strain live attenuated inﬂuenza vaccine; TIV, trivalent inactivated inﬂuenza vaccine.
*LAIV rate minus TIV rate.
 P <0 Æ05, unadjusted for multiplicity.
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For children aged 24–35 months, similar rates of lower
respiratory and wheezing illness were observed among
LAIV recipients and their corresponding TIV or placebo
recipients (Table 5). The only exception was that in pla-
cebo-controlled studies after dose 2 in year 1, the incidence
of lower respiratory illness was signiﬁcantly lower among
LAIV recipients (rate difference, )1Æ0%; P =0 Æ03). Thus,
there was no evidence for increased lower respiratory or
wheezing illness among LAIV recipients aged 24–
35 months. When analyzed by subject region and gender,
the patterns of REs, AEs, and SAEs were consistent with
those observed in the overall population.
Discussion
This integrated safety analysis of Ann Arbor strain LAIV
supports the overall safety of the vaccine in children aged
2–17 years. The large, integrated study population provided
increased statistical power to detect small differences associ-
ated with initial vaccination and revaccination across mul-
tiple studies and multiple seasonal formulations. The
analysis also provides a consensus assessment of the
expected events post-vaccination. This analysis, in which
data were integrated from multiple studies across multiple
years using multiple vaccine strains, is based on the
assumption that LAIV and TIV reactogenicity and safety
are consistent across different annual formulations of the
vaccine. Results from individual studies have demonstrated
that the safety proﬁles of the vaccines are consistent across
formulations; however, minor differences in reactogenicity
could exist between different annual formulations, and as a
result, the safety proﬁle of any particular formulation could
differ slightly from the aggregated experience reported here.
Runny⁄stuffy nose was the primary factor contributing
to the overall occurrence and distribution of reactogenicity
Table 4. Adverse events (AEs) after LAIV and placebo administration in placebo-controlled studies
AEs
Year 1, dose 1 Year 1, dose 2 Year 2
LAIV,
n (%)
Placebo,
n (%)
Rate
difference*
LAIV,
n (%)
Placebo,
n (%)
Rate
difference*
LAIV,
n (%)
Placebo,
n (%)
Rate
difference*
Total number of events 1380 841 893 657 955 482
Subjects reporting ‡1 event 975 (29Æ7) 559 (27Æ6) 2Æ2 616 (24Æ3) 460 (26Æ5) )2Æ2 624 (27Æ2) 336 (26Æ8) 0Æ4
Events by organ class with absolute rate difference ‡0Æ10%
General disorders and
administration site conditions
318 (9Æ7) 152 (7Æ5) 2Æ2
  147 (5Æ8) 119 (6Æ9) )1Æ1 206 (9Æ0) 97 (7Æ7) 1Æ3
Injury, poisoning and
procedural complications
25 (0Æ8) 8 (0Æ4) 0Æ41 3 ( 0 Æ5) 6 (0Æ3) 0Æ24 ( 0 Æ2) 5 (0Æ4) )0Æ2
Psychiatric disorders 30 (0Æ9) 12 (0Æ6) 0Æ31 5 ( 0 Æ6) 9 (0Æ5) 0Æ12 1 ( 0 Æ9) 6 (0Æ5) 0Æ4
Nervous system disorders 13 (0Æ4) 4 (0Æ2) 0Æ25 ( 0 Æ2) 2 (0Æ1) 0Æ14 ( 0 Æ2) 0 (0Æ0) 0Æ2
Reproductive system and
breast disorders
5( 0 Æ2) 0 (0Æ0) 0Æ22 ( 0 Æ1) 0 (0Æ0) 0Æ11 ( 0 Æ0) 0 (0Æ0) 0Æ04
Metabolism and nutrition
disorders
11 (0Æ3) 6 (0Æ3) 0Æ04 13 (0Æ5) 8 (0Æ5) 0Æ11 5 ( 0 Æ7) 3 (0Æ2) 0Æ4
Immune system disorders 3 (0Æ1) 2 (0Æ1) )0Æ01 0 (0Æ0) 2 (0Æ1) )0Æ10 ( 0 Æ0) 0 (0Æ0)
Ear and labyrinth disorders 7 (0Æ2) 5 (0Æ2) )0Æ03 1 (<0Æ1) 6 (0Æ3) )0Æ3
  6( 0 Æ3) 6 (0Æ5) )0Æ2
Infections and infestations 388 (11Æ8) 243 (12Æ0))0Æ2 288 (11Æ4) 228 (13Æ1) )1Æ8 230 (10Æ0) 124 (9Æ9) 0Æ1
Eye disorders 14 (0Æ4) 13 (0Æ6) )0Æ21 8 ( 0 Æ7) 5 (0Æ3) 0Æ48 ( 0 Æ3) 3 (0Æ2) 0Æ1
Skin and subcutaneous tissue
disorders
17 (0Æ5) 16 (0Æ8) )0Æ31 5 ( 0 Æ6) 11 (0Æ6) )0Æ04 13 (0Æ6) 2 (0Æ2) 0Æ4
Gastrointestinal disorders 98 (3Æ0) 67 (3Æ3) )0Æ37 0 ( 2 Æ8) 34 (2Æ0) 0Æ84 6 ( 2 Æ0) 30 (2Æ4) )0Æ4
Respiratory, thoracic and
mediastinal disorders
285 (8Æ7) 188 (9Æ3) )0Æ6 198 (7Æ8) 137 (7Æ9) )0Æ1 255 (11Æ1) 135 (10Æ7) 0Æ4
Events of interest
Lower respiratory illness 58 (1Æ8) 37 (1Æ8) )0Æ14 8 ( 1 Æ9) 51 (2Æ9) )1Æ0
  40 (1Æ7) 19 (1Æ5) 0Æ2
Wheezing illness 22 (0Æ7) 14 (0Æ7) 0Æ01 6 ( 0 Æ6) 18 (1Æ0) )0Æ41 7 ( 0 Æ7) 7 (0Æ6) 0Æ2
LAIV, Ann Arbor strain live attenuated inﬂuenza vaccine.
*LAIV rate minus placebo rate.
 P <0 Æ05, unadjusted for multiplicity.
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LAIV recipients had an approximate 10% increased inci-
dence of runny⁄stuffy nose post-vaccination. Other reac-
togenicity events more common in LAIV recipients than in
placebo recipients were headache, tiredness⁄decreased activ-
ity, and decreased appetite; however, these events were not
increased compared with TIV recipients, perhaps because
TIV also induced systemic reactogenicity. Solicited AEs that
occurred more commonly in the LAIV group were those
similar to the reactogenicity events associated with LAIV,
namely headache, nasal congestion⁄rhinorrhea, and rhinitis;
pyrexia was also associated with LAIV. Ear pain and lower
respiratory illness were decreased among LAIV recipients.
A consistent trend across all reactogenicity events and AEs
was that rate differences were lower after revaccination in
years 1 and 2 compared with the initial vaccination, a phe-
nomenon that has been noted previously in children and
adults receiving LAIV.
14–16
Fever, collected by daily temperature readings as a solic-
ited reactogenicity event, was not statistically increased in
LAIV recipients in this integrated analysis; however, more
LAIV recipients than placebo recipients reported pyrexia as
an unsolicited AE term after the ﬁrst dose. Although a few
individual studies noted a statistically signiﬁcant increase in
low-grade fevers in LAIV subjects compared with placebo
or TIV recipients after dose 1,
3,17,18 fever rates were similar
in other studies.
4,5,19–21 In addition, an early study of LAIV
reported increased rates of vomiting or abdominal pain in
LAIV recipients; however, the incidence of abdominal pain
was not actively solicited from subjects in that study.
18 In
other studies, some of which actively solicited the incidence
of abdominal pain, the rates of vomiting and abdominal
Table 5. Adverse Events (AEs) and SAEs because of lower respiratory illness and wheezing in children 24–35 months of age
AEs, days 0–10
Year 1 Year 2
Dose 1 Dose 2
LAIV,
n (%)
Comparator,
n (%)
Rate
difference*
LAIV,
n (%)
Comparator,
n (%)
Rate
difference*
LAIV,
n (%)
Comparator,
n (%)
Rate
difference*
TIV-controlled studies
Lower respiratory illness 33 (2Æ0) 45 (2Æ7) )0Æ72 7 ( 2 Æ5) 28 (2Æ6) )0Æ1N A N A N A
Wheezing illness 23 (1Æ4) 27 (1Æ6) )0Æ29 ( 0 Æ8) 13 (1Æ2) )0Æ4N A N A N A
Placebo-controlled studies
Lower respiratory illness 58 (1Æ8) 37 (1Æ9) )0Æ14 8 ( 1 Æ9) 51 (2Æ9) )1Æ0
  23 (2Æ2) 9 (1Æ6) 0Æ6
Wheezing illness 22 (0Æ7) 14 (0Æ7) 0Æ01 6 ( 0 Æ6) 18 (1Æ0) )0Æ49 ( 0 Æ8) 5 (0Æ9) 0Æ0
SAEs
Year 1 Year 2
LAIV,
n (%)
Comparator,
n (%)
Rate
difference*
LAIV,
n (%)
Comparator,
n (%)
Rate
difference*
TIV-controlled studies, days 0–42
Lower respiratory illness 9 (0Æ55) 9 (0Æ55) 0Æ00 NA NA NA
Wheezing illness 3 (0Æ18) 2 (0Æ12) 0Æ06 NA NA NA
TIV-controlled studies, days 0–180
Lower respiratory illness 29 (1Æ29) 19 (1Æ17) 0Æ12 NA NA NA
Wheezing illness 6 (0Æ37) 3 (0Æ18) 0Æ18 NA NA NA
Placebo-controlled studies, day 0–42
Lower respiratory illness 13 (0Æ41) 8 (0Æ42) )0Æ01 4 (0Æ38) 3 (0Æ52) )0Æ15
Wheezing illness 7 (0Æ22) 4 (0Æ21) 0Æ01 1 (0Æ09) 0 (0Æ00) 0Æ09
Placebo-controlled studies, day 0–180
Lower respiratory illness 28 (1Æ17) 15 (0Æ97) 0Æ20 7 (0Æ66) 4 (0Æ70) )0Æ04
Wheezing illness 9 (0Æ38) 5 (0Æ32) 0Æ05 2 (0Æ19) 0 (0Æ00) 0Æ19
LAIV, Ann Arbor live attenuated inﬂuenza vaccine; AE, adverse event; SAE, serious AE; TIV, trivalent inactivated inﬂuenza vaccine.
*LAIV rate minus comparator rate.
 P <0 Æ05, unadjusted for multiplicity.
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ents.
3–5,17,19–21 In this integrated analysis, no statistically
signiﬁcant increase in vomiting or abdominal pain was
observed among LAIV recipients.
There was no evidence of an increase in any potential
vaccine-related SAE in LAIV recipients compared with TIV
or placebo recipients. Additionally, there was no evidence
that lower respiratory illness or wheezing illness occurred
at a higher rate in LAIV subjects; this was true for children
aged 2–17 years and those aged 24–35 months. This ﬁnding
is consistent with a study that prospectively tracked the
incidence of medically attended wheezing.
3 Although an
increased rate of wheezing was seen among LAIV recipients
aged 6–23 months through 42 days after the last dose
(LAIV, 5Æ9%; TIV, 3Æ8%; P <0 Æ01), no increase was seen in
children aged 24–59 months (LAIV, 2Æ1%; TIV, 2Æ5%;
P =0 Æ38), even when the incidence was analyzed by indi-
vidual-month cohorts.
14
In conclusion, the current integrated analysis provides a
broad assessment of the overall safety and tolerability of
Ann Arbor strain LAIV in children aged 2–17 years across
multiple populations, seasons, and formulations. The
results support the safety of Ann Arbor strain LAIV in eli-
gible children aged 2–17 years and provide healthcare pro-
viders with a valuable consensus summary of events that
can be expected after vaccine administration.
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